Spruce Biosciences Inc (SPRB)

$60.06 +0.16 (0.27%)
Market Cap 82.40M
Revenue (ttm) 4.91M
Net Income (ttm) -53.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,080.24%
Debt to Equity Ratio 0.10
Volume 30,000
Avg Vol 39,864
Day's Range N/A - N/A
Shares Out 1.37M
Stochastic %K 52%
Beta 3.62
Analysts Strong Sell
Price Target $198.25

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 655 4168
Address:
611 Gateway Boulevard, Suite 740, South San Francisco, United States
Jakcofalltrades
Jakcofalltrades Mar. 16 at 2:28 AM
$SPRB who’s buying this shit
0 · Reply
History101
History101 Mar. 9 at 10:29 PM
$SPRB 4,993 watching 3/9/2026
0 · Reply
ShakeThatMoneyMaker
ShakeThatMoneyMaker Mar. 9 at 3:40 PM
$SPRB sold my 1k shares here at 61. Took a fat loss here but Im not sticking around for another 1M shares of dilution. Current float prior to this was only 1.1M. Gotta admit when you are wrong sometimes
2 · Reply
FilingTracker
FilingTracker Mar. 9 at 11:34 AM
$SPRB Offering - up to $75 million: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097569/sprb-424b5-2026.htm
0 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 11:05 AM
$SPRB Spruce Biosciences reported financial results for the year ended December 31, 2025, and provided corporate updates. The company announced that its BLA submission for TA-ERT for the treatment of Sanfil…
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 11:05 PM
$SPRB Current Stock Price: $54.27
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:16 PM
$SPRB Spruce Biosciences (NASDAQ: SPRB) just gained key FDA clarity ahead of its planned BLA submission for tralesinidase alfa. With accelerated approval potential, orphan drug upside, and rare pediatric disease incentives back in play, could this small-cap biotech stock be setting up for a major re-rating? https://biotechhealthx.com/biotech-news/is-it-a-great-choice-to-buy-spruce-biosciences-sprb-shares/
0 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 5:39 PM
.@SqueezeSharkie moving different. .Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $TOVX $SPRB $IPHA $EVGN *^
0 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 4:21 PM
$PXS $SPRB $AAOI $AGRZ +•+•
0 · Reply
Benalish
Benalish Feb. 23 at 3:09 AM
$SPRB
0 · Reply
Latest News on SPRB
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Mar 9, 2026, 7:05 AM EDT - 6 days ago

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Mar 9, 2026, 7:00 AM EDT - 6 days ago

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Mar 2, 2026, 4:05 PM EST - 13 days ago

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Feb 18, 2026, 7:00 AM EST - 25 days ago

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 4:05 PM EST - 26 days ago

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Feb 5, 2026, 4:05 PM EST - 5 weeks ago

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Feb 3, 2026, 8:00 AM EST - 5 weeks ago

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Jan 28, 2026, 8:00 AM EST - 6 weeks ago

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Jan 18, 2026, 7:02 PM EST - 2 months ago

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Jan 8, 2026, 8:00 AM EST - 2 months ago

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Dec 15, 2025, 8:00 AM EST - 3 months ago

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 4 months ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)

Oct 7, 2025, 10:38 AM EDT - 5 months ago

Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 7, 2025, 9:44 AM EDT - 5 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Sep 15, 2025, 7:00 AM EDT - 6 months ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Jakcofalltrades
Jakcofalltrades Mar. 16 at 2:28 AM
$SPRB who’s buying this shit
0 · Reply
History101
History101 Mar. 9 at 10:29 PM
$SPRB 4,993 watching 3/9/2026
0 · Reply
ShakeThatMoneyMaker
ShakeThatMoneyMaker Mar. 9 at 3:40 PM
$SPRB sold my 1k shares here at 61. Took a fat loss here but Im not sticking around for another 1M shares of dilution. Current float prior to this was only 1.1M. Gotta admit when you are wrong sometimes
2 · Reply
FilingTracker
FilingTracker Mar. 9 at 11:34 AM
$SPRB Offering - up to $75 million: https://www.sec.gov/Archives/edgar/data/1683553/000119312526097569/sprb-424b5-2026.htm
0 · Reply
StockNews_Live
StockNews_Live Mar. 9 at 11:05 AM
$SPRB Spruce Biosciences reported financial results for the year ended December 31, 2025, and provided corporate updates. The company announced that its BLA submission for TA-ERT for the treatment of Sanfil…
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 2 at 11:05 PM
$SPRB Current Stock Price: $54.27
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 1 at 3:16 PM
$SPRB Spruce Biosciences (NASDAQ: SPRB) just gained key FDA clarity ahead of its planned BLA submission for tralesinidase alfa. With accelerated approval potential, orphan drug upside, and rare pediatric disease incentives back in play, could this small-cap biotech stock be setting up for a major re-rating? https://biotechhealthx.com/biotech-news/is-it-a-great-choice-to-buy-spruce-biosciences-sprb-shares/
0 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 5:39 PM
.@SqueezeSharkie moving different. .Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $TOVX $SPRB $IPHA $EVGN *^
0 · Reply
6GodEnergy
6GodEnergy Feb. 23 at 4:21 PM
$PXS $SPRB $AAOI $AGRZ +•+•
0 · Reply
Benalish
Benalish Feb. 23 at 3:09 AM
$SPRB
0 · Reply
PortfolioObelisk
PortfolioObelisk Feb. 20 at 2:04 PM
$SPRB Spruce Biosciences develops endocrine therapies. Clinical validation drives valuation. Early-stage risk remains high.
0 · Reply
ILuvbiotech
ILuvbiotech Feb. 20 at 5:24 AM
$SPRB Many people became millionaires holding this, the next runner is $NWBO
3 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 12:45 AM
$SPRB RSI: 29.11, MACD: -5.7053 Vol: 10.30, MA20: 75.80, MA50: 79.01 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
theflynews
theflynews Feb. 19 at 5:06 PM
Biotech Alert: Searches spiking for these stocks today - $SPRB - https://legacy.thefly.com/permalinks/entry.php/id4296596
0 · Reply
TheBasedTrader
TheBasedTrader Feb. 19 at 4:14 PM
$SPRB one last major bullet going in. +300 shares totaling 600.
0 · Reply
ErikTon
ErikTon Feb. 19 at 2:39 PM
$SPRB going to 45$
0 · Reply
Benalish
Benalish Feb. 19 at 2:11 PM
$SPRB HC Wainwright drops PT by 10% exactly how much it should have dropped, not 40% lol
0 · Reply
DARKP00L
DARKP00L Feb. 19 at 12:20 PM
$SPRB 07:14 on Feb. 19 2026 HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $200 #tradeideas
0 · Reply
Benalish
Benalish Feb. 19 at 4:01 AM
$SPRB
0 · Reply
Benalish
Benalish Feb. 19 at 3:26 AM
$SPRB https://finance.yahoo.com/news/coty-downgraded-spruce-biosciences-initiated-143317044.html
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 18 at 11:54 PM
$SPRB long bag holding wait from here
0 · Reply
mikesterz7
mikesterz7 Feb. 18 at 9:32 PM
$SPRB Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.
0 · Reply